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(T2DM), few data exist describing its management in Dubai. This
study characterized the treatment and estimated levels of glycemic,
lipid, and blood pressure control among a sample with T2DM at a
large Dubai Hospital. Methods: This retrospective cohort study
systematically sampled charts from adults seeking care for T2DM
from October 2009 to March 2010 until the target (N ¼ 250) was
reached. Data on patient characteristics, pharmacotherapy, compli-
cations, and laboratory testing were abstracted until September 2011.
The frequency of treatments and modiﬁcations over the period was
calculated, and measures of glycosylated hemoglobin A1c, low-
density lipoprotein, and blood pressure control were compared with
guideline targets. Frequencies of complications were compared
according to treatment type. Results: One-third of the cohort com-
prised men, and the mean age was 58 years. At enrolment, the mean
time from T2DM diagnosis was nearly 15 years and 74% had receivedee front matter Copyright & 2015, International S
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Halifax, NS, Canada B3H 1V7.insulin. During the study period, the most common regimens were
insulin þ oral combinations (55%) and oral combination therapy
(39%). Overall, 67% received any insulin therapy during the study;
and by study end, 78% had received insulin at any time. At the most
recent assessment, guideline targets for glycosylated hemoglobin
A1c, blood pressure, and low-density lipoprotein were met by 23%,
29%, and 71%, respectively. Complications were more frequent
among those treated with combination or insulin therapies. Con-
clusions: This study provides baseline data from Dubai for future
comparisons of the effectiveness of new treatments, and to better
understand the humanistic and economic burden of T2DM and its
complications.
Keywords: diabetes, glycemic control, treatment, United Arab Emirates.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Type 2 diabetes mellitus (T2DM) is a growing health problem
worldwide, with incidence rates increasing in both developed
and developing countries [1]. In the United Arab Emirates
(UAE), the occurrence of T2DM has risen dramatically in recent
years and its population now has among the highest preva-
lence of T2DM globally, with 19% to 25% of the population
affected [2,3]. In addition to the enormous epidemiologic
burden, the economic burden associated with the treatment
and management of T2DM is substantial; it is estimated that
7% to 13% of global health care budgets will be spent onmanaging diabetes and its complications by the year 2025 [1].
In countries with high prevalences, this ﬁgure may be as high
as 40% [1].
A major contributor to the clinical and economic burden of
T2DM is the management of its associated complications, both
macrovascular (i.e., cardiovascular disease) and microvascular (i.
e., retinopathy, nephropathy, neuropathy, and diabetic foot) [4].
The risk of developing macrovascular and microvascular compli-
cations is increased among persons with T2DM who have poor
lipid, blood pressure, and in particular glycemic control [5].
Accordingly, meeting target levels on these measures, deﬁned
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ment of persons with T2DM.
Much information has been published on treatment practices
and achievement of treatment targets among persons with T2DM
in the United States and other developed countries where T2DM
has been a long-standing public health concern. Despite the
growing epidemiologic and economic burden of T2DM in the
UAE, little is known about how persons with T2DM are managed
in clinical practice and the frequency of attainment of guideline
targets for glycemic, lipid, and blood pressure control [7–9].
Documenting existing treatment patterns and treatment tar-
get success is important to provide baseline information by
which to evaluate new treatments and disease management
practices and to track changes in measures of disease control
and the economic burden over time.
We undertook a retrospective observational study to quanti-
tatively characterize contemporary treatment patterns and
measures of treatment success among persons with T2DM in
Dubai, UAE. The primary objective here was to characterize
treatment patterns according to treatment modality and to
estimate the proportion of subjects successfully controlling blood
glucose, lipid, and blood pressure levels between 2009 and 2011
among persons being managed for T2DM in Dubai, UAE. Secon-
dary objectives were to 1) estimate the impact of age, sex,
duration of T2DM, and therapy type on the proportion of subjects
meeting guideline targets; 2) describe treatment modiﬁcations
according to the duration of T2DM and previous therapy use; and
3) measure the frequency of microvascular and macrovascular
complications.Methods
This retrospective cohort study was conducted among a sample
of persons with T2DM who were being managed at a single
diabetes outpatient clinic operating in the Dubai Hospital in
Dubai, UAE; this secondary and tertiary care hospital is the
largest general medical and surgical hospital in the emirate
of Dubai.
Subjects
The target population was persons being treated for T2DM in
Dubai, UAE. To be eligible for inclusion, subjects were required to
have a diagnosis of T2DM according to ADA criteria [5], be 18
years of age or older, and of UAE nationality. Subjects enrolled in
clinical trials and women who were pregnant during the study
period were not eligible.
Electronic medical records of persons with T2DM were iden-
tiﬁed by International Classiﬁcation of Diseases, Ninth Revision codes
(250.x0, 250.x2), and a random sample was systematically
included by selecting every nth chart from the Dubai Hospital
database, which contained records for the more than 5000
persons managed at the hospital’s diabetes clinic. Medical charts
identiﬁed from the database were then screened for eligibility on
the basis of subjects attending physician visits at the study site
during the 6-month study enrolment period (October 1, 2009, to
March 3, 2010). Systematic sampling and eligibility screening
continued until the target number of 250 eligible charts was
reached.
Because the Dubai Hospital is a secondary and tertiary care
center, subjects may have been initially diagnosed at the study
site or referred from another clinical site; the study sample would
therefore represent a mix of subjects more recently diagnosed
with T2DM and those with long-standing disease.
The study protocol was approved by the Research Ethical
Approval Committee at the Dubai Hospital.Study Period
Data were collected on treatments and outcomes from all eligible
subjects during the follow-up period, which ended September 30,
2011. Eligible subjects had to visit the study site during the
enrolment period, from October 1, 2009, to March 31, 2010. This
allowed a minimum of 18-month follow-up for subjects enrolled
at the end of the enrolment period. The study enrolment date
was deﬁned as a subject’s most recent visit to the study site
during the accrual period.
Data Collected
The following data were abstracted from the paper copies of
charts of eligible subjects: 1) demographic and clinical character-
istics from the time of T2DM diagnosis and at study enrolment;
for those not diagnosed at the study site, time of diagnosis was
based on reports from the referring physician; 2) types of
pharmacotherapy (i.e., treatments) administered before study
enrolment and the type, dosage, and timing of treatments
administered between study enrolment and censoring (Septem-
ber 30, 2011); 3) the presence of microvascular (retinopathy,
peripheral neuropathy, nephropathy, chronic kidney disease,
and diabetic foot) or macrovascular (angina, previous stroke/
transient ischemic attack, coronary artery disease, peripheral
vascular disease, myocardial infarction, and congestive heart
failure) complications at study enrolment and during the study
period; and 4) results of glycosylated hemoglobin (Hb A1c), low-
density lipoprotein (LDL), blood pressure, high-density lipopro-
tein, triglyceride, and total cholesterol tests from the time of
study enrolment to censoring.
Treatment types were classiﬁed as oral monotherapy, oral
combination therapy, insulin monotherapy, insulin combination
therapy, or insulin plus oral combination therapy. Treatment
regimens were deﬁned as the unique combination of speciﬁc
drugs (including metformin, glibenclamide, gliclazide, glimepir-
ide, rosiglitazone, pioglitazone, acarbose, miglitol, repaglinide,
nateglinide, exenatide, sitagliptin, vildagliptin, or insulin);
changes in treatment were deﬁned as either regimen changes
(change in treatment regimen through the replacement, removal,
or addition of drugs) or regimen modiﬁcation (deﬁned as a
change in the dose of an existing treatment regimen).
Data collection was performed by two trained data abstrac-
tors. No subject identiﬁers were abstracted from the charts, and a
unique identiﬁer was assigned for each subject. All case report
forms were checked for completeness, and those with missing
data were checked against the source data. At least 50% of the
case report forms completed by each abstractor per day were
checked against the source data; if discordance between the
abstractors was more than 20%, all case report forms completed
that day were validated against the source data.
Sample Size
Sample size calculations were based on the ability of the study to
detect treatments and events of prespeciﬁed frequencies. The
target sample size of 250 had a 92% chance of detecting treat-
ments or events occurring with a 1% frequency and a 100%
chance of detecting treatments or events occurring with more
than 5% frequency [10].
Analysis
Descriptive statistics were generated for baseline characteristics
at study enrolment including age, sex, T2DM duration (time from
diagnosis date to study enrolment date), site of T2DM diagnosis,
immediate relatives with T2DM, Hb A1c level of less than 7%,
previous T2DM treatments (prescriptions documented in the
Table 1 – Characteristics of subjects with T2DM at
the time of study enrolment, at the Dubai Hospital
(October 2009 to March 2010).
Characteristic Subjects with T2DM
(N ¼ 250), n (%)
Sex
Male 82 (32.8)
Female 168 (67.2)
Age (y)
Mean  SD 58.3  11.9
18–34 5 (2.0)
35–49 48 (19.2)
50–64 125 (50.0)
Z65 72 (28.8)
T2DM duration (y)*
Mean  SD 14.2  7.6
o5 29 (11.6)
5–9 55 (15.6)
10–19 106 (46.0)
420 60 (26.8)
First diagnosed at study site 111 (44.4)
Immediate relatives with T2DM 54 (21.6)
Meeting Hb A1c target (o7%)† 56 (22.4)
Previous T2DM treatments received‡
Metformin 213 (85.2)
Insulin 186 (74.4)
Sulfonylureas 144 (57.6)
TZDs 62 (24.8)
DPP-4 inhibitors 22 (8.8)
Meglitinides 9 (3.6)
Alpha-glucosidase inhibitors 5 (2.0)
GLP-1 agonists 5 (2.0)
None 1 (0.4)
Comorbidities/complications
Microvascular complications 41 (16.4)
Macrovascular complications 18 (7.2)
DPP, dipeptidyl peptidase; GLP, glucagon-like peptide; Hb A1c,
glycosylated hemoglobin A1c; T2DM, type 2 diabetes mellitus;
TZDs, thiazolidediones.
*Time since diagnosis, calculated as the time from the diagnosis
date to the study enrolment date.
†Treatment target identiﬁed by the American Diabetes Association
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macrovascular complications (diagnosis documented in subject
chart before or at study enrolment date).
Types of treatment regimens, their frequency of use, as well as
the number of treatment modiﬁcations (either drug change
[replacement, removal, or addition] or dose change) over the study
period were calculated and were stratiﬁed by T2DM duration and
previous treatment at enrolment. Treatment types were classiﬁed
as oral monotherapy (e.g., metformin, a sulfonylurea, thiazolidi-
nedione, meglitinide, alpha-glucosidase inhibitor, or dipeptidyl
peptidase 4 inhibitor); oral combination therapy (two or more oral
medications used in combination); insulin monotherapy (one type
of insulin, used alone); insulin combination therapy (two or more
types of insulin used in combination); or insulin plus oral combi-
nation therapy (one or more types of insulin used in combination
with one or more oral medications). Subjects may have been
treated with more than one treatment type over the study period.
Levels of glycemic, lipid, and blood pressure control were
calculated from the ﬁrst and last measurements during the study
period. The percentages of subjects meeting ADA and UAE
National Diabetes Guidelines [5,6] target levels for Hb A1c (o7%),
LDL (o100 mg/dL), and blood pressure (o130/80 mm Hg) tests
were calculated and stratiﬁed by sex, age, T2DM duration, and
therapy type (categorized as insulin-treated or non–insulin-
treated on the basis of the most recent T2DM therapy regimen
in the study period). Poor glycemic control was deﬁned as an Hb
A1c level of 9% or more; hypertension was deﬁned as systolic
blood pressure of 140 mm Hg or more and/or diastolic blood
pressure of 90 mm Hg or more.
The number and percentage of subjects achieving differing
levels of control on Hb A1c, LDL, and blood pressure tests, from
enrolment to censoring, were calculated and stratiﬁed by T2DM
duration and by treatment type during the study period. Levels of
control were categorized as well controlled (target met on 100% of
the tests), partially controlled (target met on 50% of the tests), or
never controlled (target met on 0% of the tests).
Frequencies of microvascular and macrovascular complica-
tions, during the study period and at study end, were calculated
and compared using the chi-square test according to treatment
type at the beginning and end of the study period. The number
and percentage of subjects achieving differing levels of control on
Hb A1c, LDL, and blood pressure tests, from enrolment to censor-
ing, were also calculated and stratiﬁed by complication status at
the end of the study period.and the UAE National Diabetes Guidelines [5,6].
‡Therapies used alone or in combination with other agents.Results
A total of 422 T2DM charts were screened, of which 250 (59%)
were from eligible subjects with T2DM. The most common
reasons for ineligibility were that the subject did not visit the
study site during the enrolment period (50% of the excluded
subjects) or did not have a conﬁrmed diagnosis of T2DM accord-
ing to ADA criteria (41%). Among the 250 eligible subjects, one-
third were men, mean age at enrolment was 58  12 years, and
mean time from T2DM diagnosis was nearly 15 years (Table 1).
Baseline characteristics stratiﬁed by previous treatment type are
presented in Appendix Table 1 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2015.08.006. The duration of
T2DM was longer, and the frequency of complications at baseline
higher, among those previously treated with insulin than among
those who were insulin naive.
Treatment Patterns
At study enrolment, the most common previous treatments
included metformin, insulin, and sulfonylureas, which were usedby 58% to 85% of the subjects (Table 2). More subjects with long-
standing (Z20 years) T2DM had previously received insulin
therapy than did those recently diagnosed (o5 years) with
T2DM (83% vs. 55%, respectively). During the study period, more
than half of the subjects were treated with insulin plus oral
combination therapy and nearly 40% received oral combination
therapy. Two-third of the subjects received any insulin therapy,
and nearly twice as many subjects with long-standing T2DM
were treated with insulin compared with those with newly
diagnosed T2DM.
By study end, approximately three-quarter of the subjects had
received insulin therapy at any time, either before or during the
study period. Most subjects underwent a modiﬁcation to their
treatment regimen during the minimum 18 months of follow-up
per subject (92%; data not shown). On average, subjects with
T2DM had one drug change and nearly three drug or dose
changes over the study period (Table 2). Little variation was seen
by T2DM duration. Data on treatments prescribed and treat-
ment modiﬁcations, stratiﬁed by previous treatment type, are
Table 2 – Types and frequencies of treatments prescribed to subjects with T2DM, overall and by T2DM duration,
at the Dubai Hospital (October 2009 to September 2011).
Type of therapy or change in
therapy
T2DM duration (y)
All subjects with
T2DM (N ¼ 250)
o5
(N ¼ 29)
5–9
(N ¼ 55)
10–20
(N ¼ 106)
Z20
(N ¼ 60)
Any insulin therapy
Previous therapy, at enrolment 186 (74.4) 16 (55.2) 33 (60.0) 87 (82.1) 50 (83.3)
During study period 167 (66.8) 13 (44.8) 23 (41.8) 79 (74.5) 52 (86.7)
At study end (cumulative) 196 (78.4) 18 (62.1) 34 (61.8) 92 (86.8) 52 (86.7)
Treatment type*
Oral monotherapy 23 (9.2) 5 (17.2) 9 (16.4) 8 (7.5) 1 (1.7)
Oral combination therapy 97 (38.8) 17 (58.6) 36 (65.5) 35 (33.0) 9 (15.0)
Insulin monotherapy 28 (11.2) 0 (0.0) 4 (7.3) 11 (10.4) 13 (21.7)
Insulin combination therapy 37 (14.8) 2 (6.9) 4 (7.3) 19 (17.9) 12 (20.0)
Insulin and oral combination therapy 138 (55.2) 12 (41.4) 20 (36.4) 68 (64.2) 38 (63.3)
Most recent treatment type in the study period
Oral monotherapy 9 (3.6) 2 (6.9) 3 (5.5) 4 (3.8) 0 (0.0)
Oral combination therapy 77 (30.8) 14 (48.3) 29 (52.7) 26 (24.5) 8 (13.3)
Insulin monotherapy 16 (6.4) 0 (0.0) 1 (1.8) 5 (4.7) 10 (16.7)
Insulin combination therapy 25 (10.0) 1 (3.4) 3 (5.5) 13 (12.3) 8 (13.3)
Insulin and oral combination therapy 123 (49.2) 12 (41.4) 19 (34.5) 58 (54.7) 34 (56.7)
Number of treatment modiﬁcations
Drug change, mean  SD 1.4  1.2 1.2  1.2 1.5  1.1 1.5  1.3 1.1  1.1
Drug change, median (IQR) 1.0 (2.0) 1.0 (2.0) 1.0 (1.0) 1.0 (1.0) 1.0 (2.0)
Drug/dose change, mean  SD 2.7  1.6 2.5  1.6 2.4  1.5 2.9  1.6 2.9  1.7
Drug/dose change, median (IQR) 3.0 (2.0) 2.0 (2.0) 2.0 (2.0) 3.0 (2.0) 3.0 (2.0)
Most common treatment regimens†
Metformin þ insulin þ insulin 42 (16.8) 4 (13.8) 6 (10.9) 21 (19.8) 11 (18.3)
Metformin þ insulin 37 (14.8) 2 (6.9) 4 (7.9) 19 (17.9) 12 (20.0)
Insulin þ insulin 42 (16.8) 3 (10.3) 3 (5.5) 22 (20.8) 14 (23.3)
Metformin þ gliclazide þ sitagliptin 32 (12.8) 6 (20.7) 12 (21.8) 12 (11.3) 2 (3.3)
Insulin 28 (11.2) 0 (0.0) 4 (7.3) 11 (10.4) 13 (21.7)
Note. Values are n (%) unless indicated otherwise.
IQR ¼ interquartile range; T2DM, type 2 diabetes mellitus.
*Subjects may have received more than one type of treatment during the study period.
†Where insulin is listed more than once, it indicates that two different forms of insulin were used.
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at http://dx.doi.org/10.1016/j.vhri.2015.08.006. Although, as
expected, treatment patterns differed according to previous
treatment type, the frequency of changes in therapy was fairly
consistent across the previous treatment type groups.
T2DM Control and Treatment Target Success
Overall, levels of LDL control were high, with nearly three-quarter
of the subjects meeting guideline targets; levels of blood pressure
and glycemic control were lower, with less than one-third of the
subjects meeting targets (Table 3). Still, modest improvements
were seen in the percentage of subjects meeting guideline targets
for Hb A1c and LDL over the study period. Conversely, nearly half
of the subjects had hypertension at study end, and approximately
one-quarter of the subjects had poor glycemic control. Levels of
HDL, triglycerides, and total cholesterol at the ﬁrst and last
measurements during the study period are presented, stratiﬁed
by T2DM duration, in Appendix Table 3 in Supplemental Materi-
als found at http://dx.doi.org/10.1016/j.vhri.2015.08.006. Over the
study period, Hb A1c was well controlled in 7% of the subjects and
never controlled in 59% (see Appendix Table 4 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2015.08.006).
The proportion of subjects who were never controlled for Hb
A1c increased with T2DM duration, from approximately half of
newly diagnosed subjects to three-quarter of those with long-standing disease. The percentage of subjects achieving differing
levels of Hb A1c, LDL, and blood pressure control, stratiﬁed by
treatment type, are summarized in Appendix Table 5 in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.vhri.2015.08.
006.
The percentage of subjects with T2DM meeting guideline
targets for Hb A1c, LDL, and blood pressure at the most recent
assessment during the study period was similar between
men and women and across age categories (see Appendix
Fig. 1A,B in Supplemental Materials found at http://dx.doi.org/
10.1016/j.vhri.2015.08.006). More non–insulin-treated subjects
met guideline targets for Hb A1c, LDL, and blood pressure than
did insulin-treated subjects, particularly for Hb A1c (47% vs.
11%, respectively) (see Appendix Fig. 1C). There was little
variation in achievement of LDL and blood pressure targets
across T2DM duration categories; however, the percentage of
subjects meeting Hb A1c targets decreased as the T2DM dura-
tion increased, from 31% among newly diagnosed subjects to
10% among those with long-standing T2DM (Table 3; see
Appendix Fig. 1D).
Complications
The number of subjects with reported microvascular (n ¼ 41
[16.4%]) or macrovascular (n ¼ 18 [7.2%]) complications at study
enrolment was low; during the study period, four (1.6%) subjects
Table 3 – The n (%) of subjects with T2DM meeting ADA and UAE guideline clinical targets on measures of T2DM
control, at ﬁrst and last measurement over the study period with last measurement stratiﬁed by T2DM
duration, at the Dubai Hospital (October 2009 to March 2010).
Clinical measure* All subjects with
T2DM (N ¼ 250)
Last visit, by T2DM duration (y)
First visit Last visit o5 5–9 10–19 Z20
Hb A1c N ¼ 250 N ¼ 250 N ¼ 29 N ¼ 55 N ¼ 106 N ¼ 60
Mean  SD 8.3  1.7 8.3  1.8 8.0  1.8 7.9  1.7 8.6  2.0 8.2  1.5
Hb A1c o7 (target) 56 (22.4) 58 (23.2) 9 (31.0) 20 (36.4) 22 (20.8) 7 (10.4)
Hb A1c Z7 and o9 120 (48.0) 124 (49.6) 13 (44.8) 25 (45.5) 45 (42.5) 41 (68.3)
Hb A1c Z9 74 (29.6) 68 (27.2) 7 (24.1) 10 (18.2) 39 (36.8) 12 (20.0)
LDL (mg/dL) N ¼ 245 N ¼ 245 N ¼ 28 N ¼ 55 N ¼ 104 N ¼ 58
Mean  SD 96.7  36.4 91.3  31.9 92.2  39.2 95.7  31.3 88.8  31.4 91.0  29.9
o100 (target) 149 (60.8) 173 (69.2) 20 (71.4) 36 (65.5) 75 (72.1) 42 (72.4)
Z100 96 (39.2) 72 (28.8) 8 (28.6) 19 (34.5) 29 (27.9) 16 (27.6)
Blood pressure (mm
Hg)
N ¼ 244 N ¼ 244 N ¼ 29 N ¼ 52 N ¼ 105 N ¼ 58
Mean  SD 137.0/72.5 
19.1/10.4
138.7/72.9 
18.4/12.2
142.9/77.4 
16.0/14.3
135.6/73.4 
13.4/10.0
139.0/72.8 
20.2/12.8
138.7/70.1 
19.9/11.3
o130/80 (target) 79 (32.4) 74 (29.6) 3 (10.3) 17 (32.7) 36 (34.3) 18 (31.0)
Z130/80 and
o140/90†
48 (19.7) 46 (18.4) 8 (27.6) 14 (26.9) 16 (15.2) 8 (13.8)
Z140/90‡ 117 (48.0) 124 (49.6) 18 (62.1) 21 (40.4) 53 (50.5) 32 (55.2)
Note. Values are n (%) unless indicated otherwise.
Hb A1c, glycosylated hemoglobin A1c; LDL, low-density lipoprotein; T2DM, type 2 diabetes mellitus.
*Five (2.0%) subjects had no recorded laboratory test results during the study period for LDL, and 6 (2.4%) subjects had no blood pressure
results. All subjects had at least one test result for Hb A1c recorded during the study period.
†If systolic blood pressure Z130 mm Hg or diastolic blood pressure Z 80 mm Hg, but o140 mm Hg and o90 mm Hg, respectively.
‡If systolic blood pressure is Z140 mm Hg or diastolic blood pressure Z90 mm Hg.
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(2.8%) developed microvascular complications. At study end, a
total of 22 (8.8%) subjects with T2DM had experienced macro-
vascular complications, including angina (4.4%), stroke or tran-
sient ischemic attack (1.6%), myocardial infarction (1.2%),
coronary artery disease (1.2%), and peripheral vascular disease
(1.2%). Microvascular complications were diagnosed in 46 (18.4%)
subjects with T2DM by study end, and included retinopathy
(8.4%), nephropathy (6.8%), peripheral neuropathy (2.4%), chronic
kidney disease (5.6%), and diabetic foot (1.6%). As expected, the
occurrence of microvascular or macrovascular complications was
more frequent among those treated with combination or insulin
therapies (see Appendix Table 6 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2015.08.006). Although the pro-
portions of subjects achieving Hb A1c control was similar between
those with and without complications, more subjects without
complications achieved better blood pressure control, whereas
more subjects experiencing complications had better LDL control
(see Appendix Table 7 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.vhri.2015.08.006).Discussion
T2DM is a substantial and growing health problem both globally
and in the UAE, which now has among the highest prevalence of
T2DM in the world. Despite the considerable clinical and eco-
nomic burden associated with the disease, little is known about
how persons with T2DM in the UAE are managed in clinical
practice or the frequency with which they attain guideline targets
for glycemic, lipid, and blood pressure control. In this retrospec-
tive study, insulin was the most common treatment choice for
managing those with T2DM, most frequently in conjunction withoral combination therapy; modiﬁcations were regularly
attempted to improve T2DM control, and there were modest
improvements in the percentage of subjects meeting glycemic
and lipid control targets from study start to study end. Overall,
levels of control for LDL were good, whereas levels of blood
pressure and glycemic control were less so. There was a trend
toward decreasing glycemic control with increasing disease
duration.
This retrospective cohort study is the ﬁrst to characterize
contemporary treatment patterns and levels of treatment target
success among persons with T2DM in Dubai. Until very recently,
there has been a paucity of published observational studies
describing these outcomes among subjects with T2DM in the
UAE and the Middle East region although some local evidence is
now available. Nearly all published studies have been conducted
in the emirate of Abu Dhabi, and the reported percentage of
persons with T2DM meeting guideline treatment targets, how-
ever, has varied. Two recent studies from the UAE—one cross-
sectional and one prospective—reported that 35% to 40% of the
subjects with diabetes were treated with insulin. Although
insulin use was more frequent in the present study, there were
notable differences in the sociodemographic and clinical charac-
teristics of the study populations, including T2DM duration,
which may limit the comparability [7,11]. Overall, these ﬁndings
support the expectation that persons with long-standing T2DM
would be more likely to receive treatment with insulin than do
those with newly diagnosed T2DM.
Three studies reported that guideline Hb A1c targets were met
by 33% to 45% of the subjects with diabetes in Abu Dhabi and
blood pressure targets by 42% to 83% of the subjects [8,9,12]. One
study reported that LDL targets were achieved by 70% of the
subjects [8]. Glycemic and blood pressure control rates were
higher than in the present study, and LDL control rates were
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target success between the different measures were consistent
with the present study.
Among these studies and the present study, there were
differences in the sociodemographic and clinical characteristics
of the samples, the study setting (i.e., hospital vs. population-
based), and the criteria by which subjects with T2DM were
identiﬁed (i.e., physician diagnosis vs. self-report), which may
account for some of the variation seen between studies. The
components and location of diabetic care were also found to be
an important determinant of diabetic control in a study from
primary health care centers with chronic disease clinics in Al Ain,
UAE [13]. This ﬁnding is of interest because in a separate study of
the present cohort of patients, we found that quality of care
received was not a signiﬁcant predictor of whether an individual
would meet treatment targets. These discrepant ﬁndings could
reﬂect a difference in patterns of care between primary, and
secondary or tertiary, health care centers [14].
The results of the present study extend upon the existing
evidence by describing treatment patterns and levels of treat-
ment target success among persons managed for T2DM in Dubai.
An important additional consideration for diabetes care in the
UAE, which was not easily addressed with the design of the
present study, is the impact of fasting during Ramadan on
clinical outcomes. Modiﬁcation of diabetic treatment regimens
during Ramadan is common, occurring in 30% to 50% of the
patients. How fasting and related treatment modiﬁcations impact
the ability to achieve treatment targets, however, remains
unclear [15]. Understanding rates of achieving guidelines targets
is important because treating to target has been demonstrated to
help reduce the humanistic and economic burden associated
with T2DM and its complications [16].
This study collected real-world data on contemporary treat-
ment patterns and attainment of guideline treatment targets
among a sample of persons with T2DM managed at a diabetes
outpatient clinic in a large hospital in Dubai. At the time of study
initiation, the sample size of 250 subjects was larger than in other
published observational studies of T2DM that had been con-
ducted in the UAE. Although the results of a few studies from the
UAE with similar or larger sample sizes are now becoming
available [7,8], none was conducted in Dubai. Strengths of the
present study were the implementation of standardized proce-
dures for data collection and analysis; training of data abstractors
to ensure consistent methodology; and implementation of qual-
ity checks to ensure data completeness, quality, and consistency
between reviewers. Extracted data were checked daily between
abstractors and against source data to resolve outstanding issues.
There are several potential limitations of the present study.
First, by including only one urban study site, the results of this
study may not be representative of the experiences of all persons
with T2DM in the UAE, particularly those from rural settings. The
Dubai Hospital, however, is the largest general medical and
surgical hospital in the emirate of Dubai, and it is likely that this
study would capture a range of treatments that are generally
representative of treatment options for persons with T2DM in
Dubai. Second, the study population had long-standing T2DM
and nearly three-quarter of the subjects were diagnosed more
than 10 years before study start. Hence, ﬁndings from this study
may not be generalizable to those with a more recent diagnosis of
T2DM. Persons with newly diagnosed T2DM, particularly those
not managed at a tertiary care center, may have less severe
disease and higher rates of glycemic, lipid, and blood pressure
control; therefore, the ﬁndings of this study may overestimate
the burden of T2DM. Third, we required that subjects had an
International Classiﬁcation of Diseases, Ninth Revision diagnosis code
for diabetes as well as met the ADA diagnostic criteria, to
increase the homogeneity of the sample and to ensure thatpersons with type 1 diabetes were not included. Imposing this
restriction, however, may have excluded persons with newly
diagnosed T2DM or those with less severe disease who did not
meet these thresholds.
To our knowledge, this study is the ﬁrst to describe contem-
porary treatment patterns and levels of treatment target success
among persons managed for T2DM in Dubai. Given the increased
risk of developing macrovascular and microvascular complica-
tions associated with poor glycemic, lipid, and blood pressure
control, higher rates of persons with T2DM meeting guideline
targets for these measures, glycemic control in particular, have
the potential to reduce the humanistic and economic burden
associated with T2DM and its complications in the UAE. Evaluat-
ing similar outcomes among primary care centers in Dubai, and
in other jurisdictions in the area, would be important to better
understand overall treatment patterns and clinical outcomes
among those with T2DM in the Arabian Gulf. Novel therapies
have the potential to improve T2DM control among persons with
T2DM, and this study provides valuable baseline data with which
to compare the effectiveness of new T2DM treatments in
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